Table 1.
Baseline demographic and disease characteristics of all treated patients.
| Parameter | Infused patients, n =10 |
|---|---|
| Median age (IQR), years | 54 (38-69) |
| ≥ 65 years, n | 1 |
| Male, n | 6 |
| Stage at study entry III-IV, n | 9 |
| Bone marrow involvement at study entry,n | 3 |
| Bulky disease at baseline, n | 2 |
| FLIPI high (≥3) at study entry, n | 5 |
| Median time since diagnosis of FL, months | 13-98 (43) |
| Median no. of previous therapies (range) | 3 (1-4) |
| POD24 from first anti-CD20 mAb-containing therapy, n | 9 |
| Refractorya to first anti-CD20 mAb-containing therapy, n | 8 |
| Refractorya disease to last line of therapy, n | 9 |
| Previous antineoplastic therapy, n | |
| Anti-CD20 mAb + alkylating agent (same or different regimen) | 10 |
| Antracycline | 10 |
| PI3K inhibitors | 3 |
| Lenalidomide | 1 |
| Previous autologous ASCT, n | 4 |
aRefractory is defined as failure to respond to previous treatment (SD/PD as best response) or PD within 6 months of previous therapy completion. mAb, monoclonal antibody; PS, performance score; ASCT, autologous stem cell transplantation.